Masking policy

Patients, help us protect our high-risk patients - please wear a mask if you have respiratory symptoms, a positive COVID-19 test, or COVID-19 exposure.

Effective 3/13/23, ARC transitions to optional masking for our staff and physicians, with required masking during specific situations. Read more.

Renewing Medicaid Coverage Update

In response to the COVID-19 pandemic, the federal government declared a public health emergency (PHE) and passed a law that allowed you to automatically keep your Medicaid coverage (continuous Medicaid). Based on the new federal law, continuous Medicaid eligibility will end on March 31, 2023, so you need to renew your benefits when it’s time to ensure your coverage will continue if you are eligible.

Patients should look for notices from HHSC in YELLOW envelopes that say "ACTION REQUIRED" in RED lettering. Notices will come in the mail and/or via portal if clients chose electronic notices. They should respond quickly when they receive it.

If you don’t respond to renewal or information requests from HHS, you could lose your coverage.

Read more

Actualización Sobre Renovando la Cobertura de Medicaid 

Como respuesta a la pandemia de COVID-19, el gobierno federal declaró una Emergencia de Salud Pública (PHE, por sus siglas en inglés) y aprobó una ley que le permitió a usted mantener automáticamente su cobertura de Medicaid (cobertura continua de Medicaid). Según la nueva ley federal, la elegibilidad para la cobertura continua de Medicaid se terminará el 31 de marzo, de 2023, por eso necesita renovar sus beneficios cuando se llegue el momento para asegurar que su cobertura va a continuar si usted todavía es elegible.

Pacientes deben buscar avisos de la HHSC en sobres AMARILLOS con el texto “ACCIÓN REQUERIDA” en letras ROJAS. Los avisos llegarán por correo y/o a través del portal en línea si los clientes eligieron recibir avisos electrónicos. Deberían responder con rapidez cuando lo reciban. 

Si no responde a las solicitudes de renovación o de información de la HHSC, podría perder su cobertura.

Leer más

MyChart Login Help Me Book

ARC Clinical Trials

The research team at ARC is currently managing several different clinical studies. Are you interested in a particular study opportunity? Information about current study opportunities currently enrolling patients can be found below. Both ARC patients and non-ARC patients who fit the trial eligibility requirements are welcome.

Lung Cancer Screening Studies

  • Lung Cancer Screening

    ARC is looking for adult patients willing to undergo an investigational blood draw and chest CT scan for lung cancer screening. This study will support the development of a blood test to detect early stages of lung cancer for widespread use among individuals.

    About the Study

Pediatric Studies

  • Pediatric Chickenpox Vaccine

    This study is looking at different strengths of a potential new investigational vaccine against chickenpox. The study will look at how safe the vaccine is and will also determine whether it works to help prevent chickenpox in children. Children who are 12-15 months of age, in good health, and have received the first 3 doses (primary series) of a pneumococcal conjugate vaccine may qualify.

    About the Study
  • Pediatric GERD

    ARC is looking for adolescents ages 12-17 years old with GERD for a clinical research study. This study will evaluate the effect of an investigational drug on treating the symptoms associated with GERD.

    About the Study
  • Pediatric Migraine

    ARC will recruit patients from across Central Texas to enroll in this late phase clinical trial nicknamed “PIONEER-PEDS1.” This study intends to look at an investigational medication called Lasmiditan in reducing the pain of migraine headaches in children and adolescents.

    About the Study

Women’s Health Studies

  • Contraception

    CALLIOP3 is exploring whether a study medication called LPRI-CF113 is an effective birth control for women ages 13-45.

    About the Study
  • Cytomegalovirus

    Cytomegalovirus, shortened to CMV, is a leading cause of birth defects around the world. If a woman becomes infected with CMV while she is pregnant, she can pass the infection to her unborn baby. The investigational vaccine may help the body's immune system recognize and protect itself if it comes into contact with CMV in the future.

    About the Study